A Phase 2a Study to Evaluate the Effect of IW-3718 Administered Orally for 4 Weeks in Patients With GERD Not Completely Responsive to Proton Pump Inhibitors
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2015
At a glance
- Drugs IW 3718 (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 19 Oct 2015 Results presented at the American College of Gastroenterology 2015 Scientific Meeting, as per Ironwood Pharmaceuticals media release.
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Feb 2015 Top-line results published in an Ironwood Pharmaceuticals media release.